Clinical trials: Insulin
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Diabetes Mellitus, Type 2
A Clinical Trial Comparing the Efficacy and Safety of Exubera® and Lantus®
To compare efficacy and safety of Exubera® vs Lantus® in patients with type 2 diabetes mellitus.
- Trial name
- NCT00391027
- Testing
- Insulin Glargine (Lantus®), Inhaled Human Insulin (Exubera®)
- Where
- 62 sites in Belgium, Finland and 8 more
- Volunteers
- 261 people
- Sponsor
- Pfizer
Growth Disorders
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and…
- Trial name
- NCT00330668
- Testing
- rh IGF-1 (mecasermin)
- Where
- France
- Volunteers
- 114 people
- Sponsor
- Ipsen
Type2 Diabetes Mellitus
Basal Insulin Strategies Before Surgery
Many patients with Type 2 Diabetes Mellitus (T2DM) are currently being managed with Basal Insulin (BI). However, there is little evidence to support guidelines on dosing adjustments in the preoperative period.
- Trial name
- NCT03104738
- Testing
- 25% reduction of basal insulin dose
- Volunteers
- 40 people
- Sponsor
- Ohio State University
Type 2 Diabetes Mellitus
Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy
This study will provide information on the use of insulin lispro and insulin aspart in insulin pumps in participants with type 2 diabetes.
- Trial name
- NCT01474538
- Testing
- Insulin Lispro, Insulin Aspart
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
This is a randomized, open-label, active-controlled, single-dose, 3-treatment, 3-period, 3-way crossover, comparative PD and PK inpatient study in adults with T1D.
- Trial name
- NCT04074317
- Testing
- PRAM9, Regular Insulin + Pramlintide, Regular Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Xeris Pharmaceuticals
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.
This 2 arm study will assess the efficacy and safety of PEGASYS plus COPEGUS, with or without concomitant pioglitazone, on hepatitis C virus titers in treatment-naive patients with genotype 1 chronic hepatitis C, and insulin…
- Trial name
- NCT00545233
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 155 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus
This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.
- Trial name
- NCT00765817
- Testing
- exenatide
- Where
- 59 sites in United States, Greece and 4 more
- Volunteers
- 261 people
- Sponsor
- AstraZeneca
Type II Diabetes Mellitus
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
- Trial name
- NCT02592421
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 1 Diabetes
Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration
The purpose of this study is to evaluate the effectiveness of insulin delivered in the peritoneum (abdomen)by an implantable pump in Type 1 diabetics.
- Trial name
- MIP310 (NCT00211536)
- Testing
- Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
- Where
- 5 sites in United States
- Volunteers
- 107 people
- Sponsor
- Medtronic MiniMed, Inc.
Inflammation, Insulin Resistance
Mechanisms of Insulin Resistance in Humans
The Objectives of the study are to: (1)compare the inflammatory response and insulin resistance in skeletal muscles during a systemic infusion of lipid with that during a local infusion of lipid into the femoral artery.
- Trial name
- NCT00330967
- Testing
- 20% Intralipid
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Type 2 Diabetes
Pharmacogenomics of GLP1 Receptor Agonists
Healthy volunteers were recruited from the Old Order Amish population in Lancaster County, Pennsylvania. After providing informed consent, research participants were screened for eligibility.
- Trial name
- NCT05762744
- Testing
- Exenatide Injection (before the first FSIGT), Exenatide injection before the second FSIGT)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes
The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.
- Trial name
- NCT01003184
- Testing
- exenatide once weekly, insulin detemir
- Where
- 34 sites in Ireland, United Kingdom
- Volunteers
- 222 people
- Sponsor
- AstraZeneca
HIV, Metabolic Syndrome
Incidence of HANA Conditions in HIV-infected Individuals
With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy.
- Conditions
- HIV, Metabolic Syndrome, Osteopenia, Osteoporosis
- Trial name
- NCT03483584
- Where
- Hong Kong
- Volunteers
- 215 people
- Sponsor
- Chinese University of Hong Kong
Type 2 Diabetes Mellitus
A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.
- Trial name
- AWARD-CHN3 (NCT04591626)
- Testing
- Dulaglutide, Insulin Glargine
- Where
- 27 sites in China
- Volunteers
- 291 people
- Sponsor
- Eli Lilly and Company
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
An urgent need exists to find effective treatments for Alzheimer's disease (AD) that can arrest or reverse the disease at its earliest stages.
- Trial name
- NCT01767909
- Testing
- Insulin (Humulin® R U-100)
- Where
- 25 sites in United States
- Volunteers
- 240 people
- Sponsor
- University of Southern California
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose of this study is to provide information on the use of insulin lispro in insulin pumps (Continuous Subcutaneous Insulin Infusion [CSII])…
- Trial name
- NCT01109316
- Testing
- Insulin lispro 2 day reservoir in-use, Insulin lispro 6 day reservoir in-use, Insulin aspart 6 day reservoir in-use
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Assessment of Mealtime Bolus Insulin Behavior
The main purpose of this study is to estimate missed bolus insulin doses in diabetics. This is a 12-week, single-arm, outpatient, exploratory study with two study periods in Type 1 or Type 2 diabetics, with an investigational…
- Trial name
- NCT03368807
- Testing
- Continuous Glucose Monitoring, Insulin Lispro
- Where
- 6 sites in United States
- Volunteers
- 79 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.